Is Hydrochlorothiazide recalled?
Yes — there is an active recall. 47 ongoing FDA recalls mention Hydrochlorothiazide (128 total). Check the affected lots below.
Recalls are matched by product description. A recall usually affects specific lots, not every package of Hydrochlorothiazide. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
Nov 1, 2018
Class II · Moderate risk
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Aug 21, 2018
Class I · High risk
Product Mix-Up: customer complaint that a sealed bottle labeled as Hydrochlorothiazide Tablets USP 12.5 mg contained only Spironolactone Tablets USP 25 mg.
Aug 17, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Aug 17, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Aug 17, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Aug 17, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Aug 17, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 18, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 18, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 18, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 18, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 18, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 17, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 17, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 16, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 16, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 16, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 16, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 16, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 13, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 13, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 13, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 13, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 13, 2018
Class II · Moderate risk
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Jul 9, 2018
Class III · Low risk